Inhibition of Hepatitis B Virus by AAV8-Derived CRISPR/SaCas9 Expressed From Liver-Specific Promoters

Curative therapies for chronic hepatitis B virus (HBV) infection remain a distant goal, and the persistence of stable covalently closed circular DNA (cccDNA) during HBV replication is a key barrier that is hard to break through using the drugs currently approved for HBV treatment. Due to the accurac...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Microbiol
Egile Nagusiak: Yan, Kun, Feng, Jiangpeng, Liu, Xing, Wang, Hongyun, Li, Qiaohong, Li, Jiali, Xu, Tianmo, Sajid, Muhammad, Ullah, Hafiz, Zhou, Li, Zhou, Limin, Chen, Yu
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2021
Gaiak:
Microbiology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8271097/
https://ncbi.nlm.nih.gov/pubmed/34254007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmicb.2021.665184
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak